Out Of The Pipeline
Out Of The Pipeline
Acamprosate: For discomfort of early alcohol abstinence
Out Of The Pipeline
Eszopiclone: Targeting chronic insomnia
Out Of The Pipeline
Duloxetine: Dual-action antidepressant
Targeting depression’s emotional and physical symptoms
Out Of The Pipeline
Intramuscular olanzapine: Treating acute agitation in psychosis and bipolar mania
Out Of The Pipeline
Olanzapine/fluoxetine combination: Evidence for using the first treatment indicated for bipolar depression
Out Of The Pipeline
Vardenafil and tadalafil options for erectile dysfunction
Two new PDE-5 inhibitors have demonstrated efficacy and tolerability in clinical trials.
Out Of The Pipeline
Memantine: New option for advanced Alzheimer’s
NMDA receptor antagonist targets functioning, is well-tolerated, and may be combined with cholinesterase inhibitors.
Out Of The Pipeline
IM risperidone: Long-acting atypical antipsychotic
One year of biweekly injections reduced symptoms and restored function beyond the usual response to oral antipsychotics
Out Of The Pipeline
Sodium oxybate: A new way to treat narcolepsy
A legally manufactured drug with an illegal form has been shown to reduce cataplexy episodes by improving nighttime sleep.
Out Of The Pipeline
Atomoxetine: A different approach to ADHD
A nonaddictive, once-daily agent has shown efficacy in pediatric and adult ADHD. Here are insights on using the drug to its most beneficial effect...
Out Of The Pipeline
Aripiprazole: What the researchers say
Aripiprazole has demonstrated efficacy in schizophrenia, with fewer and less-severe side effects than older antipsychotics. Here are evidence-...